Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1649 1675
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17276106 | HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION | Non-Final OA | Mitsubishi Tanabe Pharma Corporation |
| 17778361 | NOVEL MULTISPECIFIC ANTIBODY FORMAT | Non-Final OA | AMGEN INC. |
| 17017576 | THERAPEUTIC COMBINATION OF 4-1 BB AGONISTS WITH ANTI-CD20 ANTIBODIES | Final Rejection | Hoffmann-La Roche Inc. |
| 17600600 | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE | Final Rejection | Board of Regents, The University of Texas System |
| 17611849 | EXPRESSION OF ANTIGEN-BINDING PROTEINS IN THE NERVOUS SYSTEM | Final Rejection | SANOFI |
| 17265731 | Enhanced Delivery of Drugs and Other Compounds to the Brain and Other Tissues | Non-Final OA | Duke University |
| 17430628 | Methods for Treating TNFa-Related Diseases | Final Rejection | Celltrion Inc. |
| 17366648 | NSP-INTERLEUKIN-10 PROTEINS AND USES THEREOF | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18158767 | METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP | Non-Final OA | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 17778168 | COMPOSITION FOR ANTICANCER TREATMENT, COMPRISING NK CELLS AND FUSION PROTEIN WHICH COMPRISES IL-2 PROTEIN AND CD80 PROTEIN | Final Rejection | GI CELL, INC. |
| 18175347 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | Non-Final OA | LEGEND BIOTECH USA INC. |
| 18260682 | ANTI-PD-L1/ANTI-CD47 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF | Non-Final OA | BEIJING HANMI PHARMACEUTICAL CO., LTD. |
| 18260596 | ANTIBODY SPECIFICALLY BINDING TO 4-1BB AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY | Non-Final OA | BEIJING HANMI PHARMACEUTICAL CO., LTD. |
| 17775492 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Non-Final OA | Seagen Inc. |
| 18021979 | PEPTIDE FOR THERAPEUTIC APPLICATIONS IN THE DERMATOLOGICAL FIELD | Non-Final OA | Dompe' Farmaceutici S.P.A. |
| 18021561 | ANALOGS OF HUMAN FIBROBLAST GROWTH FACTORS | Non-Final OA | ENERGESIS PHARMACEUTICALS, INC. |
| 18041423 | INCREASING THE EFFICACY OF BIOLOGICAL THERAPEUTIC MOLECULES | Non-Final OA | Kyon Biotech AG |
| 17926560 | CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases | Non-Final OA | AZTherapies, Inc. |
| 17756320 | CD7-CAR-T CELL AND PREPARATION AND APPLICATION THEREOF | Non-Final OA | PERSONGEN BIOTHERAPEUTICS (SUZHOU) CO., LTD. |
| 17603707 | THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE | Final Rejection | PrevEp, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy